614 related articles for article (PubMed ID: 33859638)
61. At the bench: Engineering the next generation of cancer vaccines.
Shae D; Baljon JJ; Wehbe M; Becker KW; Sheehy TL; Wilson JT
J Leukoc Biol; 2020 Oct; 108(4):1435-1453. PubMed ID: 31430398
[TBL] [Abstract][Full Text] [Related]
62. Cancer vaccines.
Bonnefoy JY
Expert Opin Ther Targets; 2004 Dec; 8(6):521-5. PubMed ID: 15584859
[TBL] [Abstract][Full Text] [Related]
63. Protein-based nanoparticles in cancer vaccine development.
Neek M; Kim TI; Wang SW
Nanomedicine; 2019 Jan; 15(1):164-174. PubMed ID: 30291897
[TBL] [Abstract][Full Text] [Related]
64. Microparticles and nanoparticles as delivery systems for DNA vaccines.
Cui Z; Mumper RJ
Crit Rev Ther Drug Carrier Syst; 2003; 20(2-3):103-37. PubMed ID: 14584521
[TBL] [Abstract][Full Text] [Related]
65. Production of Adjuvant-Loaded Biodegradable Particles for Use in Cancer Vaccines.
de Barros CM; Wafa EI; Chitphet K; Ahmed K; Geary SM; Salem AK
Methods Mol Biol; 2017; 1494():201-213. PubMed ID: 27718195
[TBL] [Abstract][Full Text] [Related]
66. Lipid-based mRNA vaccine delivery systems.
Midoux P; Pichon C
Expert Rev Vaccines; 2015 Feb; 14(2):221-34. PubMed ID: 25540984
[TBL] [Abstract][Full Text] [Related]
67. Cancer vaccine adjuvants--recent clinical progress and future perspectives.
Banday AH; Jeelani S; Hruby VJ
Immunopharmacol Immunotoxicol; 2015 Feb; 37(1):1-11. PubMed ID: 25318595
[TBL] [Abstract][Full Text] [Related]
68. Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy.
Collins JM; Redman JM; Gulley JL
Expert Rev Vaccines; 2018 Aug; 17(8):697-705. PubMed ID: 30058393
[TBL] [Abstract][Full Text] [Related]
69. Chemical adjuvants for plasmid DNA vaccines.
Greenland JR; Letvin NL
Vaccine; 2007 May; 25(19):3731-41. PubMed ID: 17350735
[TBL] [Abstract][Full Text] [Related]
70. Cancer Vaccines: A Brief Overview.
Thomas S; Prendergast GC
Methods Mol Biol; 2016; 1403():755-61. PubMed ID: 27076165
[TBL] [Abstract][Full Text] [Related]
71. Vaccine delivery--current trends and future.
Azad N; Rojanasakul Y
Curr Drug Deliv; 2006 Apr; 3(2):137-46. PubMed ID: 16611000
[TBL] [Abstract][Full Text] [Related]
72. Efficient Eradication of Established Tumors in Mice with Cationic Liposome-Based Synthetic Long-Peptide Vaccines.
Varypataki EM; Benne N; Bouwstra J; Jiskoot W; Ossendorp F
Cancer Immunol Res; 2017 Mar; 5(3):222-233. PubMed ID: 28143806
[TBL] [Abstract][Full Text] [Related]
73. Peptide-based therapeutic cancer vaccine: Current trends in clinical application.
Liu W; Tang H; Li L; Wang X; Yu Z; Li J
Cell Prolif; 2021 May; 54(5):e13025. PubMed ID: 33754407
[TBL] [Abstract][Full Text] [Related]
74. DNA Vaccines to Improve Immunogenicity and Effectiveness in Cancer Vaccinations: Advancement and Developments.
Singh AK; Malviya R
Curr Gene Ther; 2023; 23(3):170-183. PubMed ID: 36537599
[TBL] [Abstract][Full Text] [Related]
75. Nanoparticle delivery systems in cancer vaccines.
Krishnamachari Y; Geary SM; Lemke CD; Salem AK
Pharm Res; 2011 Feb; 28(2):215-36. PubMed ID: 20721603
[TBL] [Abstract][Full Text] [Related]
76. Synthetic vehicles for DNA vaccination.
van den Berg JH; Nuijen B; Schumacher TN; Haanen JB; Storm G; Beijnen JH; Hennink WE
J Drug Target; 2010 Jan; 18(1):1-14. PubMed ID: 19814658
[TBL] [Abstract][Full Text] [Related]
77. Lipid-protamine-DNA-mediated antigen delivery.
Vangasseri DP; Han SJ; Huang L
Curr Drug Deliv; 2005 Oct; 2(4):401-6. PubMed ID: 16305443
[TBL] [Abstract][Full Text] [Related]
78. Recombinant
Deng W; Lira V; Hudson TE; Lemmens EE; Hanson WG; Flores R; Barajas G; Katibah GE; Desbien AL; Lauer P; Leong ML; Portnoy DA; Dubensky TW
Proc Natl Acad Sci U S A; 2018 Aug; 115(32):8179-8184. PubMed ID: 30038013
[TBL] [Abstract][Full Text] [Related]
79. Immunoengineering through cancer vaccines - A personalized and multi-step vaccine approach towards precise cancer immunity.
Lybaert L; Vermaelen K; De Geest BG; Nuhn L
J Control Release; 2018 Nov; 289():125-145. PubMed ID: 30223044
[TBL] [Abstract][Full Text] [Related]
80. Plasmid DNA vaccines against cancer: cytotoxic T-lymphocyte induction against tumor antigens.
Pavlenko M; Leder C; Pisa P
Expert Rev Vaccines; 2005 Jun; 4(3):315-27. PubMed ID: 16026247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
